Marshall Fordyce - 08 Jan 2025 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
PRESIDENT AND CEO, Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
08 Jan 2025
Net transactions value
-$679,841
Form type
4
Filing time
10 Jan 2025, 16:06:50 UTC
Previous filing
20 Dec 2024
Next filing
20 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $28,896 +9,975 +6.9% $2.90 153,578 08 Jan 2025 Direct
transaction VERA Class A Common Stock Sale $414,297 -9,975 -6.5% $41.53 143,603 08 Jan 2025 Direct F1, F2
transaction VERA Class A Common Stock Options Exercise $16,367 +5,650 +3.9% $2.90 149,253 08 Jan 2025 Direct
transaction VERA Class A Common Stock Sale $237,489 -5,650 -3.8% $42.03 143,603 08 Jan 2025 Direct F1, F3
transaction VERA Class A Common Stock Options Exercise $5,432 +1,875 +1.3% $2.90 145,478 08 Jan 2025 Direct
transaction VERA Class A Common Stock Sale $78,750 -1,875 -1.3% $42.00 143,603 08 Jan 2025 Direct F1
holding VERA Class A Common Stock 222,030 08 Jan 2025 By GRAT

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -15,625 -2.5% $0.000000 610,926 08 Jan 2025 Class A Common Stock 15,625 $2.90 Direct F4
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -1,875 -0.31% $0.000000 609,051 08 Jan 2025 Class A Common Stock 1,875 $2.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 23, 2024.
F2 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $40.89 to $41.85, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.87 to $42.19, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.